ABSTRACT
Myelin basic protein [MBP] is one of the most important constituents of the CNS myelin sheaths. It is supposed that an autoimmune response directed against MBP is crucial in the demyelination process in patients with multiple sclerosis. Studies have proved that free anti-MBP level in CSF of MS patients is declined when the patient entered into clinical remission. Some researchers evaluate the changes in serum or CSF level of this antibody during immunomodulatory therapy; the results are different and the relation between the changes in this antibody and response to treatment is poorly investigated
The objective of this study was to assess the relation between the changes in serum level of anti-MBP and clinical remission in patients during treatment with fingolimod. 37 MS patients that were non responder to interferon and glatiramer acetate and were candidates to receive fingolimod were nominated for this study. In this study, the serum level of anti-MBP was evaluated before and after 3 and 6 months of therapy and clinical remission was assessed by changes in Expanded Disability Status Scale [EDSS] scores
The result of this study showed that MS patients, after treatment with interferon, have lower serum anti-MBP level than healthy control group and this difference is statistically significant [p =0.03]
The present study demonstrated that the serum anti-MBP level in MS patient during 6 months of treatment with fingolimod significantly decreased [p<0.001]. However, there was no significant difference in EDSS of MS patients during 6 months of treatment with fingolimod [p < 0.001]
ABSTRACT
Receiver Operating Characteristics [ROC] curves have numerous applications for identifying a cut-off point in diagnostic tests. Nonetheless, given that sometimes two cut-off points have to be specified simultaneously, the ROC curve can be used to identify such points. The Volume under the ROC Surface [VUS] serves as a criterion for the accuracy of diagnostic tests. One of the unfortunate outcomes in pregnancy is pre-term delivery; it has been noted that an increase in the level of hemoglobin in the first trimester of pregnancy could result in preterm delivery in weeks 34 to 37 and that an ongoing hemoglobin increase could result in the delivery of a premature fetus before the 34th week of pregnancy. In this regard, in order to separate three groups of on-time delivery, pre-term delivery and immature delivery two cut-off points have to be identified, simultaneously. A suitable measure to identify such points is the ROC surface. In the current study, the hemoglobin information of the first trimester of pregnancy and delivery time of 623 pregnant ladies referring to Milad Hospital in Tehran in 2009-2010 was obtained. ROC surface was adopted to draw two ideal cut-off points for the first trimester of pregnancy. The optimal points for hemoglobin of the first trimester computed with the ROC surface were 12.54 and 13.2. While a hemoglobin rate less than 12.54 indicated an on-time delivery, a rate between the two cut-off points referred to pre-term delivery and hemoglobin more than 13.2 showed a premature fetus. The three-dimensional ROC surface is a useful tool that can visually summarize the ability of a biological marker to classify individuals between more than two groups